Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.

Published on Apr 1, 2020in American Journal of Preventive Medicine4.435
· DOI :10.1016/J.AMEPRE.2019.10.022
Angela R. Wateska16
Estimated H-index: 16
(University of Pittsburgh),
Mary Patricia Nowalk36
Estimated H-index: 36
(University of Pittsburgh)
+ 4 AuthorsKenneth J. Smith30
Estimated H-index: 30
(University of Pittsburgh)
Introduction Recommending both the conjugate and polysaccharide pneumococcal vaccines to all U.S. seniors may have little public health impact and be economically unreasonable. Public health impact and cost-effectiveness of using both vaccines in all adults aged ≥65 years were estimated compared with an alternative strategy (omitting pneumococcal conjugate vaccine in the nonimmunocompromised) and with the newly revised recommendation (giving or omitting conjugate vaccine based on patient–physician shared decision making). Methods Strategies were examined in hypothetical U.S. 65-year-old population cohorts and segmented into health states based on age- and population-specific data in a Markov state-transition model with a lifetime time horizon from a healthcare perspective. Black population cohorts were examined separately given greater illness risk and lower vaccine uptake. Model parameters came from the Centers for Disease Control Active Core Bacterial Surveillance network, National Health Interview Survey, and Nationwide Inpatient Sample data. Outcomes included incremental costs per quality-adjusted life year gained and pneumococcal disease outcomes for each strategy. Data were gathered and analysis performed in 2018. Results Giving both vaccines, either routinely or with shared decision making, was most effective, reducing pneumococcal disease incidence compared with no vaccination, but costing 765,000–.18 million/quality-adjusted life year gained. Depending on examined population and scenario, the alternative strategy cost 65,700–26,700/quality-adjusted life year gained (less in black populations) and reduced cases and deaths by 0.3%–0.9%. Conclusions A vaccination strategy that omits pneumococcal conjugate vaccine in immunocompetent U.S. seniors may be economically reasonable, particularly for black seniors. Use of both pneumococcal vaccines was more effective but substantially more expensive.
  • References (30)
  • Citations (0)
📖 Papers frequently viewed together
1 Citations
42 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
: Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). In 2014, the Advisory Committee on Immunization Practices (ACIP)* recommended routine use of PCV13 in series with PPSV23 for all adults aged ≥65 years based on demonstrated PCV13 safety and efficacy against PCV13-type pneumonia among...
333 Citations
#1Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
#2Angela R. Wateska (University of Pittsburgh)H-Index: 16
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 30
view all 7 authors...
Abstract Background Racial disparities in U.S. adult pneumococcal vaccination rates persist despite reduced barriers to access. Consequently, racial and ethnic minorities experience pneumococcal disease at higher rates than whites. This study examined prevalence of high-risk conditions and pneumococcal hospitalizations among U.S. black and non-black populations aged ≥50 years. Methods National Health Interview Survey, National Center for Health Statistics and National Inpatient Sample data were ...
2 CitationsSource
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 30
view all 7 authors...
Abstract Background Changing pneumococcal disease epidemiology due to childhood vaccination has prompted re-examination of US adult pneumococcal vaccination policies, as have considerations of greater pneumococcal disease incidence and higher prevalence of conditions that increase risk in underserved minority populations. Prior analyses suggest routine pneumococcal vaccination at age 50 could be considered, which could disproportionately benefit underserved populations. Methods A Markov cohort m...
1 CitationsSource
#1Tamara PilishviliH-Index: 1
#1Eun Ji Kim (Hofstra University)H-Index: 5
#2Taekyu Kim (Harvard University)H-Index: 2
Last. Amresh D. Hanchate (BU: Boston University)H-Index: 18
view all 6 authors...
Background There exist racial and ethnic disparities in the prevalence of chronic medical illnesses. However, it is unclear if the disparities arise from patients’ self-reported estimates on these diseases and whether there is an association between healthcare utilization and diagnosis.
5 CitationsSource
#1Dominic Thorrington (PHE: Public Health England)H-Index: 7
#2Leo G. van RossumH-Index: 8
Last. Albert Jan van Hoek (Lond: University of London)H-Index: 24
view all 7 authors...
Background Streptococcus pneumoniae causes morbidity and mortality among all ages in The Netherlands. To reduce this burden, infants in The Netherlands receive the 10-valent pneumococcal conjugated vaccine (PCV10), but older persons are not targeted. We assessed the impact and cost-effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) or 13-valent PCV (PCV13) among all those aged 60, 65 or 70 and/or in combination with replacing PCV10 with PCV13 in the infant va...
9 CitationsSource
#1Marie-Josée J. Mangen (UU: Utrecht University)H-Index: 27
#2Susanne M. Huijts (UU: Utrecht University)H-Index: 14
Last. G. Ardine de Wit (UU: Utrecht University)H-Index: 32
view all 4 authors...
The sustained health-related quality-of-life of patients surviving community-acquired pneumonia has not been accurately quantified. The aim of the current study was to quantify differences in health-related quality-of-life of community-dwelling elderly with and without community-acquired pneumonia during a 12-month follow-up period. In a matched cohort study design, nested in a prospective randomized double-blind placebo-controlled trial on the efficacy of the 13-valent pneumococcal vaccine in c...
17 CitationsSource
#1Julio A. RamirezH-Index: 46
#2Timothy WiemkenH-Index: 20
Last. Ruth CarricoH-Index: 18
view all 21 authors...
Background: Understanding the burden of community-acquired pneumonia (CAP) is critical to allocate resources for prevention, management, and research. The objectives of this study were to define incidence, epidemiology, and mortality of adult patients hospitalized with CAP in the city of Louisville, and to estimate burden of CAP in the US adult population. Methods: This was a prospective population-based cohort study of adult residents in Louisville, Kentucky, from 1 June 2014 to 31 May 2016. Co...
48 CitationsSource
#1W. W. WilliamsH-Index: 11
#2Peng-jun LuH-Index: 34
Last. Amy Parker FiebelkornH-Index: 17
view all 12 authors...
PROBLEM/CONDITION: Overall, the prevalence of illness attributable to vaccine-preventable diseases is greater among adults than among children. Adults are recommended to receive vaccinations based on their age, underlying medical conditions, lifestyle, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U....
138 CitationsSource
#1Isaac See (CDC: Centers for Disease Control and Prevention)H-Index: 11
#2Paul Wesson (University of California, Berkeley)H-Index: 4
Last. Jennifer Ahern (University of California, Berkeley)H-Index: 43
view all 13 authors...
Background: Invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) incidence in the United States is higher among black persons than white persons. We explored the extent to which socioeconomic factors might explain this racial disparity. Methods: A retrospective cohort was based on the Centers for Disease Control and Prevention's Emerging Infections Program surveillance data for invasive community-associated MRSA cases (isolated from a normally sterile site of an outpa...
13 CitationsSource
Cited By0